H.C. Wainwright says Yartemlea approval ‘significant validation’ of Omeros value

H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros (OMER) following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a “significant validation” of Omeros value. H.C. Wainwright’s current model assumed an 80% probability of success for Yartemlea in the U.S., and pricing of $150K per patient.